Background: Microsatellite instability (MIN) has been studied in a variety of carcinomas and gynecologic sarcomas, but never in musculoskeletal sarcomas.
Sarcomas are a structurally diverse group of rare, malignant connective tissue neoplasms; a total of 2500 skeletal and 6400 soft tissue sarcomas are diagnosed annually in the United States. 10steogenic sarcoma (OGS), the most common skeletal sarcoma, illustrates the heterogeneity seen in these cancers. It can occur sporadically, or in association with Paget's disease, fibrous dysplasia, osteochondromatosis, osteoblastoma, Ollier's disease, hereditary retinoblastoma, Li-Fraumeni syndrome, or after treatment with radiation or chemotherapy. OGS develops in 12% of bilateral retinoblastoma patients--approximately 2000 times the normal rate. 2~ Seventy percent of OGS patients are known to have a dysfunctional retinoblastoma gene. 5'6 Li-Fraumeni syndrome is an inherited disorder caused by a germ-line mutation of the p53 gene. People with this mutation have an unusually high incidence of sarcomas of bone and soft tissue, breast cancer, and other tumors, with 6% of those afflicted developing OGS. 7's Microsatellites are short oligonucleotide repeats that are dispersed throughout the human genome and exhibit length polymorphism. These microsatellites vary in length from person to person, but are identical in any one person. Some tumor cells show changes in the length of these microsatellites compared with normal cells, indicating that the DNA sequences have gained or lost base pairs during tumor replication. This change in allelic size is termed microsatellite instability (MIN) . Because microsatellites are highly polymorphic and are easily analyzed by polymerase chain reaction (PCR), they are valuable genetic markers for the altered phenotypes seen in cancers. Microsatellite instability has been shown to be a signal of defective DNA mismatch repair in several neoplasms. It has been reported :in tumors as different as hereditary nonpolyposis colorectal cancer and melanoma. It is not known if mismatch repair, as evidenced by MIN, plays a rote in the oncogenesis of skeletal or soft tissue sarcomas.
To determine whether MIN is present in musculoskeletal sarcomas with a particular focus on OGS, we performed microsatellite analysis on neoplastic and normal tissue from several patients with these tumors. In this paper we report our findings and compare the rate of MIN in musculoskeletal sarcomas to that seen in other neoplasms.
METHODS
Fresh or flesh-frozen neoplastic and normal control tissue was obtained intraoperatively from 16 patients (8 males and 8 females) with musculoskeletal sarcomas. Institutional Review Board approval was obtained for use of specimens from human subjects. The histogenesis of the six skeletal sarcomas and 10 soft tissue sarcomas included the following: osteogenic sarcoma (4); malignant fibrous histiocytoma (3); spindle cell sarcoma (2); liposarcoma (2); neurofibrosarcoma (1); chondrosarcoma (1); synovial cell sarcoma (1); fibrosarcoma (1); and hemangiopericytoma (1). The average age of the patients was 53 years (range 8 to 88 years; Table 1 ). DNA was extracted routinely after tissue pulverization. 9'10 Standard PCR amplification was performed on the DNA from both normal and tumor specimens at nine separate microsatellites localized to specific chromosome regions implicated in malignancies: lq32-q41 (D1S158); 5q11.2-13.3 (D5S107); 7q (D7S594); llp13-p14 (DllS904); 1tp15.2 (DllS861); 12p13.2-p13.3 (vWF-TNR); 13q14.2 (D13S170); 17p13.1 (D17S786); and 19@3.3 (DM). Heterozygosity indices were 89%, 82%, 84%, 83%, 70%, 73%, 90%, 77%, and 73%, respectively. These loci were chosen because they were areas of instability seen in other tumors studied for MIN or because they were in areas of reported cytogenetic abnormalities, such as RB and p53, which are seen in OGS. 11-15 Oligonucleotide primers in our study were obtained from Research Genetics (Huntsville, AL).
PCR was performed on 40 ng of neoplastic and control DNA following established protocols. 1° The forward primer was end-labeled with galmna 32p-ATP (Amersham Cooperation, Arlington Heights, IL) for each microsatellite. A single PCR machine, model PTC-150 (MJ Research, Inc., Watertown, MA) was used throughout this analysis.
The 10-txL reaction mixture contained 1.25 mM dNTP, 12 mM MgC12, 10x Taq buffer, Taq DNA polymerase, nuclease-free water, 2 [xm forward and reverse oligonucleotide primers, and 0.4 ~m end-labeled forward primer. End-labeling was carried out in a 0.6-mL Eppendorf tube with nuclease-free water, 5x kinase buffer, 2 Ixm forward primer, gamma 32P-ATP, and T4 polynucleotide kinase (Promega, Madison, WI). Previous experience has shown that conditions for PCR vary depending on which primer is used. For example, primer Dt 1S861 was cycled at 25 step cycles with 1 minute at 94°C, 2 minutes at 55°C, 2.5 minutes at 72°C, and 10 minutes at 72°C. Primer 17S786 underwent 27 step cycles with 1 minute at 94°C, 2 minutes at 57°C, and 2 minutes at 72°C followed by 10 minutes at 72°C. Primer DM was cycled at 35 step cycles with 30 seconds at 94°C, 75 seconds at 60°C, 15 seconds at 72°C, and 6 minutes at 72°C. All other primers were cycled at 26 step cycles with 30 seconds at 94°C, 75 seconds at the respective annealing temperature, 15 seconds at 72°C, and 6 minutes at 72°C with the annealing temperatures as tbllows: D1S158--60°C; D5S107--55°C; D7S594--58°C; DllS904--55°C; D13S170--55°C; and vWF-TNR--50°C. At the conclusion of PCR, 1.5 txL of sample was added to an Eppendorf tube containing 3 IxL of stop solution (250 1 of bromphenol blue xylene cyahole dye and 1 mL of formamide). These samples were then denatured for 7 minutes at 95°C. The samples were immediately placed on ice, and 3.0 t~L of the samples were added to a 6% acrylamide gel. The gels were run at 95 watts for 1.5 to 2.5 hours, depending on the probe. After cooling, they were transferred to gel blot paper (Mid-West Scientific, St. Louis, MO). The gel was then covered with cellophane wrap and dried at 60°C for 1 hour on a dryer. The gel was placed in an autoradiography cassette (Fisher Scientific, Pittsburgh, PA) and exposed to radiographic film for 1 to 5 days at -70°C.
RESULTS
We examined 16 sarcomas and their matched normal tissues as controls, searching for microsatellite instability at nine separate loci. Table 1 displays the clinical and biochemical data of the patients studied, including cancer histogenesis, grade, tumor location, surgical treatment, whether the specimen was pre-exposed to a potentially gene-altering antineoplastic therapy (i.e., chemotherapy or radiation), and current clinical status of the patient. Altered mobility of alleles, indicative of MIN, was seen in 7 of 16 tumors (44%), with three of these tumors showing MIN at multiple loci. Fifty percent of the skeletal sarcomas had MIN, and one high-grade OGS exhibited MIN at five of nine loci, Loss of heterozygosity was not evident in any of these tumors. Figures 1 and 2 show representative microsateltite data generated by PCR amplification of genomie DNA from normal and tumor tissue from skeletal and soft tissue sarcoma patients.
The current clinical status of patients in the study is as follows: four patients dead of disease; two patients alive with disease; and ten continuous disease-free survivors. Neither of the patients alive with disease had any loci positive for MIN, nor did six of the ten continuous disease-free survivors. Three of the four deceased patients showed MIN. Preoperatively, two of seven patients with MIN had treatment, one with chemotherapy and the other with radiation therapy. 
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DISCUSSION
Microsatellite instability, not previously explored in musculoskeletal sarcomas, was identified in 44% of our patients. MIN was seen in 50% of the skeletal sarcomas. This compares to previous studies, which identified the rate at which repetitive DNA segments undergo length changes in normal human somatic cells as 0.29%, 16 Also contrary to the previous study on gynecologic sarcomas, three of our seven patients displayed MIN at multiple loci. The presence of MIN outside the loci of known tumor suppressor oncogenes RB (13q14.2) and p53 (17p13-t3.3), and the presence of MIN at multiple loci demonstrate that many mechanisms may contribute to the oncogenesis of the numerous types of skeletal and soft tissue sarcomas and to the heterogeneity of these neoplasms.
The inherent ability of PCR to assess microsatellites facilitates the evaluation of the many types of sarcomas, including OGS. This technology may help in the genetic classification of the clinically diverse subtypes of skeletal and soft tissue sarcomas, and, therefore, help to identify significant prognostic factors that could alter treatment plans. Further studies of MIN in sarcomas and its role in oncogenesis, prognosis, and clinical management are warranted as musculoskeletal sarcomas are added to the growing list of malignancies that demonstrate somatic alterations in the repeat length of microsatellites.
